Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Marinus (MRNS) yesterday and set a price target of $22. The company’s shares closed yesterday at $3.45, close to its 52-week low of $2.36.
“Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder.”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -10.3% and a 35.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $19.
Based on Marinus’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.11 million. In comparison, last year the company had a GAAP net loss of $4.74 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
Read More on MRNS: